Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
70.23
-1.15 (-1.61%)
At close: May 9, 2025, 4:00 PM
69.00
-1.23 (-1.75%)
After-hours: May 9, 2025, 6:06 PM EDT
Corcept Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Corcept Therapeutics stock have an average target of 142, with a low estimate of 131 and a high estimate of 150. The average target predicts an increase of 102.19% from the current stock price of 70.23.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $150 → $145 | Strong Buy | Maintains | $150 → $145 | +106.46% | May 6, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $128 → $131 | Buy | Maintains | $128 → $131 | +86.53% | Apr 3, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $130 → $142 | Strong Buy | Maintains | $130 → $142 | +102.19% | Apr 1, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $76 → $150 | Strong Buy | Maintains | $76 → $150 | +113.58% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $115 → $150 | Strong Buy | Maintains | $115 → $150 | +113.58% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
923.49M
from 675.04M
Increased by 36.81%
Revenue Next Year
1.22B
from 923.49M
Increased by 32.00%
EPS This Year
1.73
from 1.23
Increased by 40.56%
EPS Next Year
3.40
from 1.73
Increased by 96.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 971.0M | 1.5B | 2.0B | ||
| Avg | 923.5M | 1.2B | 1.7B | ||
| Low | 869.3M | 1.0B | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 43.8% | 57.1% | 64.2% | ||
| Avg | 36.8% | 32.0% | 35.8% | ||
| Low | 28.8% | 12.7% | 9.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.27 | 4.37 | 7.83 | ||
| Avg | 1.73 | 3.40 | 6.22 | ||
| Low | 1.29 | 2.13 | 3.66 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 84.4% | 152.6% | 130.1% | ||
| Avg | 40.6% | 96.9% | 82.8% | ||
| Low | 5.2% | 23.0% | 7.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.